W Western Governors University
AO · 5 4 3 D
College of Health Professions
EST. 1997
A NEW KIND OF U
D345 OA Study from course tips
O BJ E CT I V E A SS E SS M E N T R E V I E W — PSYC H O P H A R M ACO LO G Y E SS E N T I A LS
INSTITUTION Western Governors University COURSE CODE D345
PROGRAM PMHNP — Psychopharmacology ACADEMIC YEAR
EXAM TITLE D345 OA Study from course tips TOTAL QUESTIONS 80 Questions
COURSE TITLE Advanced Psychopharmacology FORMAT Multiple Choice — Select the
Single Best Answer
EXAMINATION INSTRUCTIONS
▸ Select the single best answer for each question.
▸ Neurotransmitters, psychiatric disorders, receptor pharmacology, withdrawal management, CYP450
system, antipsychotics, antidepressants, and mood stabilizers are all testable content.
▸ EPS, NMS, long-acting injectables, and substance use disorder treatments are emphasized for the OA.
▸ Correct answers and clinical rationales appear below each question for comprehensive OA preparation.
▸ All content reflects WGU D345 course tips and PMHNP board examination standards.
, SECTION I — D345 OA: NEUROTRANSMITTERS THROUGH
Questions 1 – 80
TREATMENT GUIDELINES
1. Serotonin (5-HT) is primarily involved in:
A. Reward, pleasure, and movement
B. Mood, sleep, and appetite
C. Alertness, energy, and stress response
D. Memory and muscle movement
CORRECT ANSWER B — Mood, sleep, and appetite
RATIONALE Serotonin (5-HT) is the neurotransmitter most associated with mood regulation,
sleep-wake cycles, and appetite control. It is produced primarily in the raphe
nucleus and projects widely throughout the brain. Most antidepressants (SSRIs,
SNRIs) target serotonin by blocking its reuptake. Low serotonin is implicated in
depression, anxiety, OCD, and insomnia. Dopamine (Choice A) mediates reward
and pleasure. Norepinephrine (Choice C) mediates alertness and stress.
Acetylcholine (Choice D) mediates memory and muscle movement.
Understanding neurotransmitter functions is foundational D345 content — it
guides medication selection based on which symptoms (and thus which
neurotransmitter systems) need to be targeted.
,2. Neuroleptic Malignant Syndrome (NMS) is characterized by:
A. Hyperreflexia, clonus, and agitation
B. Rigid muscles, confusion, dysphagia, gradual onset, high fever, elevated CPK, WBC, and
LFTs
C. Restlessness and inability to stay still
D. Involuntary facial movements after long-term antipsychotic use
CORRECT ANSWER B — Rigid muscles, confusion, dysphagia, gradual onset, high fever,
elevated CPK, WBC, and LFTs
RATIONALE NMS is a life-threatening idiosyncratic reaction to antipsychotics (especially high-
potency FGAs like haloperidol). Key features: severe muscle rigidity ("lead pipe"),
confusion, dysphagia, mutism, high fever, autonomic instability, elevated CPK
(muscle breakdown), leukocytosis, and elevated LFTs. Treatment: immediate
discontinuation of the antipsychotic, bromocriptine (dopamine agonist),
dantrolene (muscle relaxant), and ICU supportive care. NMS is distinguished from
serotonin syndrome (Choice A) which presents with hyperreflexia and clonus (not
rigidity). Akathisia (Choice C) is restlessness. Tardive dyskinesia (Choice D)
involves involuntary movements after chronic use. The NMS vs. serotonin
syndrome distinction is a critical D345 OA concept.
, 3. An antagonist does what at a receptor?
A. Activates the receptor with full effect
B. Blocks the receptor
C. Activates the receptor weakly
D. Reduces receptor activity below baseline
CORRECT ANSWER B — Blocks the receptor
RATIONALE An antagonist binds to a receptor but does NOT activate it — it blocks the
receptor, preventing endogenous neurotransmitters or agonist drugs from
binding and producing effects. This is the mechanism of most antipsychotics (D2
antagonists), many blood pressure medications (beta-blockers), and opioid
reversal agents (naloxone). An agonist (Choice A) activates the receptor with full
effect. A partial agonist (Choice C) activates weakly — aripiprazole is the classic
example. An inverse agonist (Choice D) reduces receptor activity below baseline.
The agonist-antagonist-partial agonist-inverse agonist spectrum is fundamental
receptor pharmacology — D345 OA questions frequently test the ability to classify
drugs by their receptor actions.
AO · 5 4 3 D
College of Health Professions
EST. 1997
A NEW KIND OF U
D345 OA Study from course tips
O BJ E CT I V E A SS E SS M E N T R E V I E W — PSYC H O P H A R M ACO LO G Y E SS E N T I A LS
INSTITUTION Western Governors University COURSE CODE D345
PROGRAM PMHNP — Psychopharmacology ACADEMIC YEAR
EXAM TITLE D345 OA Study from course tips TOTAL QUESTIONS 80 Questions
COURSE TITLE Advanced Psychopharmacology FORMAT Multiple Choice — Select the
Single Best Answer
EXAMINATION INSTRUCTIONS
▸ Select the single best answer for each question.
▸ Neurotransmitters, psychiatric disorders, receptor pharmacology, withdrawal management, CYP450
system, antipsychotics, antidepressants, and mood stabilizers are all testable content.
▸ EPS, NMS, long-acting injectables, and substance use disorder treatments are emphasized for the OA.
▸ Correct answers and clinical rationales appear below each question for comprehensive OA preparation.
▸ All content reflects WGU D345 course tips and PMHNP board examination standards.
, SECTION I — D345 OA: NEUROTRANSMITTERS THROUGH
Questions 1 – 80
TREATMENT GUIDELINES
1. Serotonin (5-HT) is primarily involved in:
A. Reward, pleasure, and movement
B. Mood, sleep, and appetite
C. Alertness, energy, and stress response
D. Memory and muscle movement
CORRECT ANSWER B — Mood, sleep, and appetite
RATIONALE Serotonin (5-HT) is the neurotransmitter most associated with mood regulation,
sleep-wake cycles, and appetite control. It is produced primarily in the raphe
nucleus and projects widely throughout the brain. Most antidepressants (SSRIs,
SNRIs) target serotonin by blocking its reuptake. Low serotonin is implicated in
depression, anxiety, OCD, and insomnia. Dopamine (Choice A) mediates reward
and pleasure. Norepinephrine (Choice C) mediates alertness and stress.
Acetylcholine (Choice D) mediates memory and muscle movement.
Understanding neurotransmitter functions is foundational D345 content — it
guides medication selection based on which symptoms (and thus which
neurotransmitter systems) need to be targeted.
,2. Neuroleptic Malignant Syndrome (NMS) is characterized by:
A. Hyperreflexia, clonus, and agitation
B. Rigid muscles, confusion, dysphagia, gradual onset, high fever, elevated CPK, WBC, and
LFTs
C. Restlessness and inability to stay still
D. Involuntary facial movements after long-term antipsychotic use
CORRECT ANSWER B — Rigid muscles, confusion, dysphagia, gradual onset, high fever,
elevated CPK, WBC, and LFTs
RATIONALE NMS is a life-threatening idiosyncratic reaction to antipsychotics (especially high-
potency FGAs like haloperidol). Key features: severe muscle rigidity ("lead pipe"),
confusion, dysphagia, mutism, high fever, autonomic instability, elevated CPK
(muscle breakdown), leukocytosis, and elevated LFTs. Treatment: immediate
discontinuation of the antipsychotic, bromocriptine (dopamine agonist),
dantrolene (muscle relaxant), and ICU supportive care. NMS is distinguished from
serotonin syndrome (Choice A) which presents with hyperreflexia and clonus (not
rigidity). Akathisia (Choice C) is restlessness. Tardive dyskinesia (Choice D)
involves involuntary movements after chronic use. The NMS vs. serotonin
syndrome distinction is a critical D345 OA concept.
, 3. An antagonist does what at a receptor?
A. Activates the receptor with full effect
B. Blocks the receptor
C. Activates the receptor weakly
D. Reduces receptor activity below baseline
CORRECT ANSWER B — Blocks the receptor
RATIONALE An antagonist binds to a receptor but does NOT activate it — it blocks the
receptor, preventing endogenous neurotransmitters or agonist drugs from
binding and producing effects. This is the mechanism of most antipsychotics (D2
antagonists), many blood pressure medications (beta-blockers), and opioid
reversal agents (naloxone). An agonist (Choice A) activates the receptor with full
effect. A partial agonist (Choice C) activates weakly — aripiprazole is the classic
example. An inverse agonist (Choice D) reduces receptor activity below baseline.
The agonist-antagonist-partial agonist-inverse agonist spectrum is fundamental
receptor pharmacology — D345 OA questions frequently test the ability to classify
drugs by their receptor actions.
